Managing atypical hemolytic uremic syndrome: chapter 2.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 25951068.
- Also identified by DOI 10.1038/ki.2015.60.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Licht et al. present the 2-year follow-up data of the landmark trials studying the efficacy of eculizumab in the treatment of atypical hemolytic uremic syndrome (aHUS). They report sustained improvements in hematologic parameters, continued safety, and additional improvements in kidney function with extended treatment. This report adds a layer of comfort to our care of patients with this rare disease; however, it is unlikely to be the final chapter in the treatment of aHUS.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Atypical Hemolytic Uremic Syndrome